Effects of TMZ-Se and TMZ on tumor growth in mouse glioma and melanoma xenograft models.

<p>(<b>A and B</b>) The human glioma cells LN229 (1×10⁵ cells in 15 µl of DMEM medium) were injected into the brains of 6-week-old male BALB/c nude mice at 4 mm depth under anesthesia with chloralic hydras (4%, 2ml/kg, ip). Three days after tumor cell implantation, mice were randomly divided into three groups (15 mice/group). Treatments were begun on day 4. TMZ-SE (15 mg/kg), TMZ (15 mg/kg) or vehicle (10% DMSO in saline) was given p.o. daily for 2 weeks. (<b>A</b>) At day 7 and day 21 after tumor cell implantation, the mice were euthanized, and the brains were fixed in 10% buffered formalin, embedded in paraffin, and then stained with hematoxillin-eosin (H&E). The images shown are the representative of 5 mice from each group; (<b>B</b>) The kaplan-Meier survival curves, n = 10; (<b>C</b>) Nude mice (swiss^nu/nu) were inoculated s.c. with UACC903 human melanoma cells (1×10⁶ cells/100 µl/mouse). When the tumors reached 50∼100 mm³ in volume, TMZ or TMZ-Se (15 mg/kg) was administered i.p. on days 1, 3, 5, 7 and 9. Tumor sizes and body weight of the animals were measured every other day. The differences between treatments were analyzed using a two-sample <i>t</i>-test. The survival curves of the tumor - bearing mice subjected to different treatments were estimated using Kaplan-Meier method and compared by log-rank statistic analysis.